Erasca, Inc. Appoints Dr. Charles Fuchs as President, Research & Development

What Happened
Erasca, Inc. (Nasdaq: ERAS) announced in an 8-K filed Aug. 10, 2026 that Charles S. Fuchs, M.D., M.P.H. was appointed President, Research & Development effective August 10, 2026. Dr. Fuchs joins with decades of oncology leadership experience, most recently serving as Chief Medical Officer of Tubulis GmbH and previously as Global Head of Oncology & Hematology Product Development at Genentech/Roche.

Key Details

• Annual base salary: $570,000; annual target bonus: 45% of base salary.
• Equity grant: stock options to purchase 1,300,000 shares; vesting over four years (25% after one year, then monthly thereafter). 1,278,520 options granted under the newly adopted 2026 Employment Inducement Incentive Award Plan (Inducement Plan); the remaining 21,480 options under the 2021 Incentive Award Plan. Exercise price = Nasdaq closing price on grant date.
• Inducement Plan adopted effective Aug. 10, 2026; 6,200,000 shares reserved for awards. Plan adopted without stockholder approval under applicable Nasdaq listing rules and limits inducement awards to new or returning employees per Nasdaq exceptions.
• Dr. Fuchs is designated a “Tier 1 Covered Employee” under Erasca’s Severance and Change and Control Severance Plan and is party to the company’s standard indemnification agreement.

Why It Matters
This filing signals a key leadership hire for Erasca’s drug development strategy by adding an experienced oncology R&D leader. Compensation terms include a large stock-option grant and placement of most options under a new Inducement Plan that reserves 6.2 million shares, which is material for potential future dilution and for assessing executive alignment and expected R&D direction. The Inducement Plan’s adoption without shareholder approval follows Nasdaq rules for hiring-related awards and may enable further inducement grants to recruit senior talent.